COLOPL Group Company Brilliantcrypto Inc., Reveals “Brilliantcrypto,” The Blockchain Game Which Generates Economic Value in The Metaverse With Digital World Gemstones
25.7.2023 08:00:00 EEST | Business Wire | Press release
The wholly owned subsidiary of COLOPL, Inc. (HQ: Minato City Tokyo; CEO: Takashi Miyamoto), Brilliantcrypto, Inc. (HQ: Minato City Tokyo; CEO: Naruatsu Baba), announced its new blockchain game “Brilliantcrypto,” which introduces the new “Proof of Gaming” concept at the global Web3 conference “WebX” (held on 25/07/2023).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724611315/en/
New blockchain game "Brilliantcrypto" (Graphic: Business Wire)
Game Overview
Brilliantcrypto is a blockchain game where players around the world become miners and excavate the mines with the aim of finding gemstones and tokens. Users buy pickaxes in the in-game marketplace, and use items like the “detector” while carrying out mining. By mining, players can obtain tokens and gemstones, and there will be the possibility to bring the gemstones, which can turn into NFTs, into many different metaverse worlds. There will also be the possibility to buy and sell the gemstones, as well as use them.
What is “Proof of Gaming”?
Simply put, “Proof of Gaming” is the game model version of “Proof of Work,” which is Bitcoin’s consensus algorithm.
In Bitcoin, mining is carried out in the form of a tremendous amount of hash calculations, which in turn guarantees value on the blockchain. Similarly, in Brilliantcrypto, mining will be carried out in the form of people throughout the world playing the game, which will guarantee the value of gemstones in the digital world.
Generating Economic Value In the Metaverse with “Proof of Gaming”
The metaverse is currently being developed, and we believe that one reason that could be given for it not fully catching on yet is that there is currently no “economic value.” If the value of digital world gemstones is guaranteed by “Proof of Gaming,” it becomes possible to use them not only in-game, but also in many different metaverse worlds, and so becomes possible to exchange them and use them. Therefore, the more exchanges begin to take place, the more the demand for gemstones with value will grow, and the more people from around the world will gather to play the game. We believe that through this cycle, “Proof of Gaming” will be activated further and as a result, true economic value will be generated in the metaverse.
Realizing Sustainable Play-to-Earn
In recent years, “play-to-earn,” which made it possible to earn money while playing games using a combination of blockchain technology and cryptocurrency, has been gathering global attention.
On the other hand, there has existed a sustainability issue with play-to-earn, as the system only allows individual, early adopters to actually make a profit. Through guaranteeing the value of digital world gemstones with Brilliantcrypto’s “Proof of Gaming” model, societal value will be generated and brought out into the world. That is why we believe sustainable play-to-earn can finally be made a reality.
About the Closed Beta Test
We will carry out a closed beta test before the official service launch.
Therefore, from today until Monday 08/08/2023 05:59 (UTC), we are accepting applications to participate in the beta.
Closed Beta Details
- Application Period: Tues. 25/07/2023 05:00 〜 Tues. 08/08/2023 05:59 (UTC)
- Amount of spots: Limited availability expected
- Beta Test Period:
1st Test: Tues. 15/08/2023 06:00 - Tues. 22/08/2023 05:59 (UTC)
2nd Test: Tues. 12/09/2023 06:00 - Tues. 19/09/2023 05:59 (UTC)
3rd Test: Tues. 10/10/2023 06:00 - Tues. 17/10/2023 05:59 (UTC)
- Clear Reward (1): Win ¥5000 worth of ETH (receivable by all who clear)
- Clear Reward (2): Enter a lottery, where 6 lucky players will win 2 VIP tickets to watch PSG play in France, in the tournament that decides the top European football team (return flight tickets included).
Closed Beta Application Page
https://beta-user-registration.brilliantcrypto.net
Game Website
https://brilliantcrypto.net
Social Media
- Twitter https://twitter.com/Brypto_Official
- Discord https://discord.gg/x23GWNu73B
- Youtube https://www.youtube.com/@Brilliantcrypto
Company Name: Brilliantcrypto, Inc.
Headquarters: Tokyo, Minato City, Akasaka 9-7-2, 5F & 6F Midtown East
Founded: 2022/11/09
Executive Director: Naruatsu Baba
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724611315/en/
Contact information
Point of Contact regardings inquiries from the media on this release
Brilliantcrypto PR Representative: Hugo Church, Naoki Nose, Yasuhiro Noguchi
Mail：press.contact@brilliantcrypto.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom